Welcome to our dedicated page for Glycomimetics SEC filings (Ticker: GLYC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GLYC SEC filings page on Stock Titan offers access to regulatory documents associated with GlycoMimetics, Inc. before and through its business combination with Crescent Biopharma, Inc. GlycoMimetics described itself as a late clinical-stage biotechnology company focused on glycobiology-based therapies for cancers, including acute myeloid leukemia (AML), and inflammatory diseases. Its filings provide formal detail on this research focus, its investigational candidates, and the corporate transactions that culminated in the transition to Crescent Biopharma, Inc.
Key filings include current reports on Form 8-K that describe material events. For example, a June 18, 2025 Form 8-K explains that on June 13, 2025, GlycoMimetics consummated a business combination with Crescent Biopharma, Inc., and that after the merger the company changed its name to Crescent Biopharma, Inc. and its ordinary shares trade on The Nasdaq Capital Market under the symbol CBIO. This filing also outlines how GlycoMimetics and Crescent securities were converted in the merger and summarizes ownership percentages of the post-merger company.
Another Form 8-K dated July 31, 2025, filed under the Crescent Biopharma, Inc. name, describes the adoption of an executive severance plan for employees at the vice president level and above. Such filings provide insight into governance, compensation arrangements, and the structure of executive protections in connection with corporate change-of-control events.
On Stock Titan, users can review these and other GLYC-related filings with the support of AI-powered summaries that highlight key terms, transaction structures, and governance provisions. Real-time updates from EDGAR ensure that newly filed 8-Ks and other forms associated with the historical GLYC registration are captured. For investors and researchers examining the legacy GlycoMimetics entity and its merger into Crescent Biopharma, this page serves as a focused entry point into the company’s regulatory history and the documentation of its transition to trading under CBIO.
Crescent Biopharma, Inc. received a Schedule 13G disclosing that 1Globe Capital LLC and its chairman, Jiaqiang Li, report shared beneficial ownership of 896,712 ordinary shares, representing 6.45% of the outstanding class based on 13,892,562 shares. The filing states the shares are held with shared voting and dispositive power and that the holdings were not acquired to influence control of the issuer. Reporting addresses include One International Place, Boston, MA, while the issuer’s principal office is listed in Waltham, MA. The Schedule is dated for the event on 08/13/2025 and signed on 08/20/2025.
CRESCENT BIOPHARMA, INC. Schedule 13G/A discloses that multiple Biotechnology Value Fund-related entities and Mark N. Lampert report shared beneficial ownership of the issuer's ordinary shares as of June 30, 2025. Individual holdings reported include Biotechnology Value Fund, L.P. (BVF) with 707,116 shares (approximately 5.1% of 13,892,562 outstanding shares), Biotechnology Value Fund II, L.P. (BVF2) with 593,740 shares (approximately 4.3%), and Biotechnology Value Trading Fund OS LP with 62,383 shares (about 0.4%). Aggregated positions held or attributable through affiliated vehicles total 1,387,863 shares, representing approximately 9.99% of the class. The filing also states that Pre-Funded Warrants exercisable for an aggregate of 597,928 shares are held by the reporting persons but could not be exercised as of June 30, 2025 due to a 9.99% exercise blocker.
Logos Global Management and related entities report ownership stakes in Crescent Biopharma, Inc. The filing shows Logos Global Management LP and Logos Global Management GP LLC each have beneficial ownership of 575,000 ordinary shares, representing 4.1% of the class. Logos Global Master Fund LP and Logos GP LLC each report 100,000 shares (0.7%). The percentage figures are calculated using 13,829,562 ordinary shares outstanding as reported by the issuer for the quarter ended June 30, 2025.
The reported positions are held with shared voting and shared dispositive power; no reporting person claims sole voting or sole dispositive power. The filers state they are investment adviser/related entities and expressly disclaim membership in a group and disclaim beneficial ownership except to the extent of pecuniary interest. The filing includes certifications that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing control.